PRTG PORTAGE BIOTECH INC

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside chat at Citi's 2023 Virtual Oncology Leadership Summit taking place on Febrarury 21 – 23, 2023. Event details are below:

Citi's 2023 Virtual Oncology Leadership Summit

Date / Time:Wednesday, February 22, 2023 at 9:00am ET
Webcast:

A replay will be available about 12 hours after the conclusion of the live fireside chat, and will be posted on the investors section of the Portage Biotech website one year following the event.

About Portage Biotech Inc.

Portage is clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. These programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. The Company’s unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products. For more information, please visit , follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations

Chuck Padala

Media Relations

Gwendolyn Schanker



EN
15/02/2023

Underlying

PRTGPORTAGE BIOTECH INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PORTAGE BIOTECH INC

 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025. Financial Results from Year Ended March 31, 2025 The Company incurred a net loss of approximately $6.8 million during the fiscal year ended Marc...

July 25, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing ...

Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. About Portage BiotechPortage Biotech is a clinical-stage i...

June 25, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech and Compedica Stock-for-Stock Exchange

Portage Biotech and Compedica Stock-for-Stock Exchange DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings Limited, a company formed under the laws of the Isle of Man (“Compedica”) entered a mutual Subscription Agreement (“Subscription Agreement”). Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501 shares of Co...

June 9, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelio...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. Dr. Luciano Mutti of the Department of Applied Clinical Sciences and Biotechnology at the University of L'Aquila, Italy, an internationally recognized expert in mesothelioma, will be presenting the data at the American Association for C...

April 28, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Promising Preclinical Results in Mesothelioma ...

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibody DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo I...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch